Category

In the news
Predicine presented data highlighting the use of PredicineCARE and PredicineATLAS in patients with metastatic breast cancer and early stage bladder cancer. Publications can be found below: (Breast Cancer Abstract) (Bladder Cancer Abstract)    
Results from the study utilizing the PredicineCARE liquid biopsy assay evaluate the concordance of somatic alterations identified by standard tissue testing to those identified by analysis of urinary circulating tumor DNA in patients with urothelial bladder cancer. The publications can be found online at: (HERE)
Results from the studies utilizing Predicine’s blood-based liquid biopsy assay to detect copy number loss in PTEN, RB1, TP53, etc. are now published in Frontiers in Oncology and JCO Precision Oncology, respectively. Predicine, Inc. announced today results from two liquid biopsy studies demonstrating the technical capability and clinical application of the PredicineCARE™ liquid biopsy NGS...
Predicine is selected as one of the top 5 liquid biopsy startup companies impacting oncology worldwide. 5 Top Liquid Biopsy Startups Impacting Oncology
Q: ONCE SEQUENCING HAS BEEN VALIDATED AS A CLINICAL SOLUTION VIA TRUSTED WORKFLOWS, AND COINCIDING WITH THE TECHNOLOGICAL DEVELOPMENTS DRIVING COSTS LOWER, WE CAN EXPECT ACCELERATED HUMAN GENOME PROFILING FOR CLINICAL DX. HOW SOON, DO YOU THINK, WILL WE SEE ACCELERATED GROWTH AND WHAT CAN WE EXPECT? A: We will see accelerated human genome profiling...
For almost every cancer, immune infiltrates are prognostic markers for better overall outcome,” says Bernard A. Fox, Ph.D., CEO of UbiVac and Harder Chair for Cancer Research, Earle A. Chiles Research Institute. Predictive biomarkers are indicators of whether a patient should get a specific therapy. The use of such biomarkers has been given various names,...